FierceBiotech5d
Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...
The Business Journals4d
Biogen details pipeline culling as it looks for more deals like HI-Bio acquisition
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.
Morningstar5d
Biogen's stock slides on soft guidance and a decline in sales of MS drugs
Better-than-expected Alzheimer's disease treatment sales and a quarterly beat were not enough to offset below-consensus EPS outlook Biogen Inc.'s stock (BIIB) tumbled 7% Wednesday, after the ...
Seeking Alpha5d
Biogen outlook disappoints amid pressure on multiple sclerosis franchise
Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...